Pfizer reportedly close to buying Medivation for $14B
Drugmaker Pfizer has nearly completed negotiations to take over Medivation, maker of a widely prescribed drug for prostate cancer, in a $14 billion cash deal, people familiar with the matter said. The drug, Xtandi, is […]